Nice

News
Card image cap

NICE okays neoadjuvant Opdivo in lung cancer

Bristol-Myers Squibb’s Opdivo has become the first immunotherapy to be cleared for NHS use alongside chemotherapy as a pre-surgery (neoadjuvant) therapy for resectable non